Integral Diagnostics (IDX) H2 2026 earnings summary

Executive summary

• Revenue grew 25.6% year-over-year to AUD 788.7 million, driven by organic growth, acquisitions, higher patient volumes, Medicare indexation, and favorable modality mix.

• Operating EBITDA increased 30.3% to AUD 164.8 million, with margin improving to 20.9%, supported by disciplined cost management and over AUD 14 million in annualized synergies from the Capitol Health integration.

• Operating NPAT rose 50.1% to AUD 47.4 million; statutory NPAT was AUD 22.0 million after non-operating and integration costs.

• Patient Net Promoter Score remained high at +81, reflecting strong patient satisfaction and clinical reputation.

• Strategic priorities for FY 2027 include margin expansion, disciplined capital management, operational excellence, and leveraging regulatory changes for growth.

Financial highlights

• Revenue increased to AUD 788.7 million from AUD 628 million in FY 2025, a 25.6% rise.

• Operating EBITDA margin improved by 80 basis points to 20.9% year-over-year.

• Operating EPS increased 23.6% to AUD 0.126 per share.

• Fully franked final dividend of AUD 0.06 per share, total FY 2026 dividend up 50% to AUD 0.093 per share.

• Free cash flow of AUD 106.4 million, up 30.7%, with 82% cash conversion.

Outlook and guidance

• FY 2027 priorities include maximizing value from the existing platform, margin improvement above 21.0%, and disciplined capital management.

• Capex expected between AUD 50 million and AUD 60 million.

• Strategic review of New Zealand operations underway, considering both improvement and potential divestment.

• Continued focus on leveraging MRI deregulation, National Lung Cancer Screening Program, and digital transformation for growth.